Aaron Sverdlov, Co-Director of the Newcastle Centre of Excellence in Cardio-Oncology at Hunter Medical Research Institute (HMRI), shared a post on LinkedIn:
“New Publication Alert
I’m pleased to share our newly published article “Cardiometabolic perturbations arising from treatment with novel anticancer therapies”, co-authored with Doan Ngo and Joshua D. Bennetts.
As cancer survivorship grows, we need to broaden cardiotoxicity thinking beyond LV dysfunction and myocarditis to the cardiometabolic effects of modern targeted therapies, particularly immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs).
Key takeaways:
– Cardiometabolic toxicities are common, clinically important, and often missed, including hyperglycaemia, dyslipidaemia, accelerated atherosclerosis, thyroid and adrenal dysfunction.
– Mechanisms are diverse and agent-specific, so a “one-size” monitoring approach won’t work.
– Guidance remains fragmented, with real-world gaps in surveillance and treatment pathways across classes and scenarios.
– Structured, proactive monitoring & management strategies, starting early and continuing through survivorship are needed.
– ICIs and TKIs save lives and significantly improve survivorship, but integrated, multidisciplinary cardio-oncology is the future to prevent and manage cardiovascular side effects.”
Title: Cardiometabolic perturbations arising from treatment with novel anticancer therapies
Authors: Joshua D Bennetts, Aaron L Sverdlov, Doan TM Ngo
Read The Full Article
More posts featuring Aaron Sverdlov on OncoDaily.